Tower Research Capital (TRC)’s Grace Therapeutics GRCE Stock Holding History
Bought
Maintained
Sold
Other funds holding GRCE
OM
Tower Research Capital (TRC)'s GRCE Position: Q3 2026 in Review
Tower Research Capital (TRC) increased its Grace Therapeutics (GRCE) stake by 37% in Q3 2026, buying an estimated $1.34K and bringing the position to 2,258 shares worth $4.86K. The position accounts for ﹤0.01% of the portfolio, ranked #4684.
Tower Research Capital (TRC) first reported a position in GRCE in Q2 2013 and has held it in 19 quarters since. The position peaked at $8.2K in Q3 2024. 37 funds tracked by Wall St. Rank hold GRCE as of Q3 2026.
- Tower Research Capital (TRC) held 2,258 shares of Grace Therapeutics worth $4.86K as of Q3 2026.
- Tower Research Capital (TRC) bought 606 Grace Therapeutics shares in Q3 2026, an estimated $1.34K.
- Grace Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #4684 holding.
- Tower Research Capital (TRC) first reported a position in Grace Therapeutics in Q2 2013 and has held it in 19 quarters since.
- Tower Research Capital (TRC)'s Grace Therapeutics position peaked at $8.2K in Q3 2024.
- 37 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.